Renal cell carcinoma (RCC) is comprised of clear-cell (ccRCC) and non-clear-cell (nccRCC) tumors. Despite definitive surgical resection in localized disease, recurrence often occurs. A commercial method based on a multiplex polymerase chain reaction (PCR) assay exclusively targets rearranged T cell receptor (TCR) genes to generate high-throughput sequencing-based data, allowing characterization of the immune repertoire within tumors. In this study we performed a retrospective analysis on archived tumor samples from patients with recurring versus non-recurring T3 ccRCC and on samples from early nccRCC versus ccRCC. Following genomic DNA extraction and multiplex PCR, the fraction of T cells within tumors, the number of unique receptors ('richness') and their relative abundances ('clonality') were calculated. Statistical significance and correlations were calculated using Student's t-test and Spearman's rho, respectively. Average fraction and clonality of T cells in tumors from non-recurring patients was 2.5- and 4.3-fold higher than in recurring patients (P = 0.025 and P = 0.043, respectively). A significant positive correlation was found between T cell fraction and clonality (Spearman's rho = 0.78, P = 0.008). The average fraction of T cells in ccRCC tumors was 2.8-fold higher than in nccRCC tumors (P = 0.015). Clonality and estimated richness were similar between ccRCC and nccRCC tumors. In summary, recurrence of ccRCC is associated with a lower fraction and clonality of T cells within tumors; nccRCC tumors are more 'deserted' than ccRCC, but similar in their ability to generate a clonal T cell repertoire. Our work suggests associations between the characteristics of T cell infiltrate, histology and tumor recurrence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274198PMC
http://dx.doi.org/10.1111/cei.13608DOI Listing

Publication Analysis

Top Keywords

nccrcc tumors
16
cells tumors
12
fraction clonality
12
tumors
9
cell receptor
8
renal cell
8
cell carcinoma
8
fraction cells
8
average fraction
8
clonality cells
8

Similar Publications

Objective: Clinical trials have demonstrated the efficacy and safety of avelumab + axitinib in patients with advanced clear cell renal cell carcinoma (ccRCC). However, information is limited regarding the activity of avelumab + axitinib in patients with non-clear cell RCC (nccRCC). In Japan, post-marketing surveillance (PMS) of patients with RCC receiving avelumab + axitinib treatment in general clinical practice was undertaken.

View Article and Find Full Text PDF
Article Synopsis
  • Renal cell carcinoma (RCC) is primarily treated through surgical options like radical or partial nephrectomy, and treatment decisions are based on histological classifications and the RENAL score, with contrast-enhanced ultrasound (CEUS) being a safer alternative to traditional imaging methods.
  • A retrospective study at Lanzhou University Second Hospital evaluated how CEUS can help in preoperatively assessing RCC histological classifications and RENAL scores by analyzing tumor features in 248 patients undergoing surgery.
  • Findings revealed that certain imaging features (hyperenhancement, heterogeneous enhancement, etc.) were significant indicators of clear cell RCC (ccRCC), suggesting CEUS has diagnostic efficacy comparable to contrast-enhanced CT in differentiating between cc
View Article and Find Full Text PDF
Article Synopsis
  • Researchers assessed circulating tumor DNA (ctDNA) as a biomarker for monitoring cancer treatment in patients with various renal cell carcinoma (RCC) types, finding it could improve clinical outcomes.
  • The study involved 92 patients undergoing treatment, monitoring ctDNA changes and their association with progression-free survival (PFS), revealing that patients with serial ctDNA negativity had better PFS compared to those who remained ctDNA positive.
  • Results indicate that regular ctDNA monitoring can provide valuable prognostic information during treatment or surveillance, showing strong correlation with patient outcomes.
View Article and Find Full Text PDF

[Non-clear cell renal cell carcinoma].

Urologie

December 2024

Medizinische Klinik II, Universitätsklinik, J.W. Goethe Universität, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Deutschland.

Non-clear cell renal cell carcinomas (nccRCC) account for approximately 20-25% of renal cell carcinomas. Approximately 20 different histologically and/or molecularly defined entities are subsumed under nccRCC. Many entities only have a share of 1% or less.

View Article and Find Full Text PDF
Article Synopsis
  • - Recent advancements in ccRCC treatment contrast with the limited research and improvements in non-clear cell renal cell carcinoma (nccRCC) therapies, highlighting a gap in understanding these cancer types.
  • - The 2022 WHO classification has redefined key nccRCC subtypes and introduced a molecular classification, which paves the way for better profiling and targeted therapies.
  • - The study reviews genomic alterations in nccRCC that could inform treatment options and emphasizes the need for personalized medicine due to the diverse nature of these cancers, as well as ongoing clinical trials for further insights.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!